Logo image of NGM

NGM BIOPHARMACEUTICALS INC (NGM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NGM - US62921N1054 - Common Stock

1.54 USD
-0.02 (-1.28%)
Last: 4/4/2024, 8:17:51 PM
1.55 USD
+0.01 (+0.65%)
After Hours: 4/4/2024, 8:17:51 PM
Fundamental Rating

3

Overall NGM gets a fundamental rating of 3 out of 10. We evaluated NGM against 192 industry peers in the Pharmaceuticals industry. While NGM has a great health rating, there are worries on its profitability. NGM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NGM has reported negative net income.
In the past year NGM has reported a negative cash flow from operations.
NGM had negative earnings in each of the past 5 years.
NGM had a negative operating cash flow in each of the past 5 years.
NGM Yearly Net Income VS EBIT VS OCF VS FCFNGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of NGM (-84.31%) is worse than 74.87% of its industry peers.
With a Return On Equity value of -95.79%, NGM perfoms like the industry average, outperforming 40.20% of the companies in the same industry.
Industry RankSector Rank
ROA -84.31%
ROE -95.79%
ROIC N/A
ROA(3y)-55.71%
ROA(5y)-41.91%
ROE(3y)-64.77%
ROE(5y)-48.77%
ROIC(3y)N/A
ROIC(5y)N/A
NGM Yearly ROA, ROE, ROICNGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NGM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGM Yearly Profit, Operating, Gross MarginsNGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

7

2. Health

2.1 Basic Checks

NGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
NGM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NGM has more shares outstanding
There is no outstanding debt for NGM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NGM Yearly Shares OutstandingNGM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
NGM Yearly Total Debt VS Total AssetsNGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -4.16, we must say that NGM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NGM (-4.16) is worse than 61.81% of its industry peers.
There is no outstanding debt for NGM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.16
ROIC/WACCN/A
WACC9.2%
NGM Yearly LT Debt VS Equity VS FCFNGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

NGM has a Current Ratio of 7.79. This indicates that NGM is financially healthy and has no problem in meeting its short term obligations.
NGM's Current ratio of 7.79 is fine compared to the rest of the industry. NGM outperforms 79.90% of its industry peers.
NGM has a Quick Ratio of 7.79. This indicates that NGM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.79, NGM belongs to the top of the industry, outperforming 80.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.79
Quick Ratio 7.79
NGM Yearly Current Assets VS Current LiabilitesNGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.10% over the past year.
NGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.02%.
The Revenue for NGM have been decreasing by -47.30% on average. This is quite bad
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y-47.3%
Sales Q2Q%-99.09%

3.2 Future

The Earnings Per Share is expected to grow by 6.98% on average over the next years.
Based on estimates for the next years, NGM will show a very strong growth in Revenue. The Revenue will grow by 69.25% on average per year.
EPS Next Y29.44%
EPS Next 2Y20.23%
EPS Next 3Y11.9%
EPS Next 5Y6.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y94.76%
Revenue Next 5Y69.25%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NGM Yearly Revenue VS EstimatesNGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2028 2029 2030 100M 200M 300M
NGM Yearly EPS VS EstimatesNGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NGM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGM Price Earnings VS Forward Price EarningsNGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGM Per share dataNGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.23%
EPS Next 3Y11.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NGM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NGM BIOPHARMACEUTICALS INC

NASDAQ:NGM (4/4/2024, 8:17:51 PM)

After market: 1.55 +0.01 (+0.65%)

1.54

-0.02 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11 2024-03-11/amc
Earnings (Next)05-02 2024-05-02/amc
Inst Owners3.6%
Inst Owner Change0%
Ins Owners1.26%
Ins Owner Change0%
Market Cap128.53M
Revenue(TTM)4.42M
Net Income(TTM)-142.38M
Analysts49.09
Price Target1.7 (10.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.62%
Min EPS beat(2)16.9%
Max EPS beat(2)18.33%
EPS beat(4)3
Avg EPS beat(4)8.18%
Min EPS beat(4)-11.04%
Max EPS beat(4)18.33%
EPS beat(8)6
Avg EPS beat(8)6.31%
EPS beat(12)8
Avg EPS beat(12)3.05%
EPS beat(16)9
Avg EPS beat(16)1.01%
Revenue beat(2)0
Avg Revenue beat(2)-73.67%
Min Revenue beat(2)-76.61%
Max Revenue beat(2)-70.73%
Revenue beat(4)0
Avg Revenue beat(4)-67.12%
Min Revenue beat(4)-76.61%
Max Revenue beat(4)-57.45%
Revenue beat(8)3
Avg Revenue beat(8)-14.9%
Revenue beat(12)4
Avg Revenue beat(12)-13.87%
Revenue beat(16)6
Avg Revenue beat(16)-10.32%
PT rev (1m)-60.88%
PT rev (3m)-60.88%
EPS NQ rev (1m)-27.96%
EPS NQ rev (3m)-27.96%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.11
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0.05
BVpS1.78
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -84.31%
ROE -95.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.71%
ROA(5y)-41.91%
ROE(3y)-64.77%
ROE(5y)-48.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.37%
Cap/Sales 28.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.79
Quick Ratio 7.79
Altman-Z -4.16
F-Score3
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)43.33%
Cap/Depr(5y)40.9%
Cap/Sales(3y)11.29%
Cap/Sales(5y)7.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y29.44%
EPS Next 2Y20.23%
EPS Next 3Y11.9%
EPS Next 5Y6.98%
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y-47.3%
Sales Q2Q%-99.09%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y94.76%
Revenue Next 5Y69.25%
EBIT growth 1Y8.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.47%
OCF growth 3YN/A
OCF growth 5YN/A

NGM BIOPHARMACEUTICALS INC / NGM FAQ

What is the ChartMill fundamental rating of NGM BIOPHARMACEUTICALS INC (NGM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NGM.


What is the valuation status of NGM BIOPHARMACEUTICALS INC (NGM) stock?

ChartMill assigns a valuation rating of 0 / 10 to NGM BIOPHARMACEUTICALS INC (NGM). This can be considered as Overvalued.


How profitable is NGM BIOPHARMACEUTICALS INC (NGM) stock?

NGM BIOPHARMACEUTICALS INC (NGM) has a profitability rating of 0 / 10.


What is the earnings growth outlook for NGM BIOPHARMACEUTICALS INC?

The Earnings per Share (EPS) of NGM BIOPHARMACEUTICALS INC (NGM) is expected to grow by 29.44% in the next year.